ÂÜÀòÂÒÂ×

Sevan Habeshian is a co-founder and CTO at Orbis Medicines, where responsibilities include building lab infrastructure to support company operations since February 2022. Prior to this, Sevan was a doctoral researcher at EPFL, contributing to advancements in macrocyclic drug discovery from September 2017 to January 2022, and conducting research that laid the groundwork for Orbis Medicines. Sevan’s earlier experience includes a role as Principal Research Associate at X-Chem, Inc., focusing on DNA-encoded libraries and drug discovery optimization from November 2010 to August 2017, along with various research positions at Brandeis University. Sevan holds a Master's degree in Organic Chemistry and a Bachelor's degree in Chemistry from Brandeis University.